Tiziana Life Sciences Ltd.: Tiziana Life Sciences Announces Continued Clinical Improvements in the Second Patient with Secondary Progressive Multiple Sclerosis (SPMS) After Six Months of Dosing with Intranasal Foralumab
The second Expanded Access patient (EA2) demonstrated improved walking as measured by gait stability and enduranceThe patient showed clinically significant improvement in the Expanded Disability Status
Source: finanznachrichten.de
